Tyra Biosciences, Inc. (TYRA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 17 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026before open 41 8-K
Q2 FY2026Tue, Aug 4, 2026after close 35 8-K
Q1 FY2026Wed, May 13, 2026before open 43 8-K
Q4 FY2025Mon, Mar 2, 2026after close 61 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Thu, Aug 14, 2025after close 45 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Thu, Mar 27, 2025after close 86 8-K

What they guided beta

Q3 FY2026 "Initiation of the study is expected in 2027, subject to regulatory feedback." exhibit
Q3 FY2026 "TYRA continues to advance enrollment and expects to report additional clinical results in 2027." exhibit
Q3 FY2026 "Initial results from the safety sentinel cohort, including six-month annualized height velocity and safety data, representing approximately 25 children in aggregate, are expected in 2027." exhibit
Q3 FY2026 "Together with existing cash resources, the financing is expected to support execution of the Company's dabogratinib 3x3 strategy, as well as ongoing research and development activities, through 2030." exhibit
Q3 FY2026 "Following its September 2026 financing, the Company expects its current financial resources to fund planned operations through 2030." exhibit
Q2 FY2026 "Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5 th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 - CARLSBAD, Calif., August 4, 2026 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a cl" exhibit
Q2 FY2026 "Initial results from this study are expected in 2027." exhibit
Q2 FY2026 "Initial results from the safety sentinel cohort, including 6-month annualized height velocity and safety data for dose levels 1-5, which will include an aggregate of approximately 25 children, are expected to be reported at the end of Q1 2027." exhibit
Q2 FY2026 "The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute on its plans into the second half of 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TYRA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TYRA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

TYRA earnings date badge

HTML

<a href="https://veritasdata.dev/company/TYRA/"><img src="https://veritasdata.dev/embed/TYRA.svg" alt="TYRA earnings date" width="240" height="56"></a>

Markdown

[![TYRA earnings date](https://veritasdata.dev/embed/TYRA.svg)](https://veritasdata.dev/company/TYRA/)

Script

<script async src="https://veritasdata.dev/embed/TYRA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TYRA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.